SPRED2, CD24, and MMP8 expression: Potential Markers for Fatty Liver Progression to Hepatocellular Carcinoma

被引：0
|
作者：
Longchamps, Ryan J. [1 ]
Abey, Sarah [1 ]
Martino, Angela C. [1 ]
Del Valle-Pinero, Arseima Y. [1 ]
Majors, Benjamin [1 ]
Henderson, Wendy A. [1 ]
机构：
[1] NINR, NIH, DHHS, Bethesda, MD 20892 USA
来源：
HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1494
引用
收藏
页码：892A / 893A
页数：2
相关论文
共 50 条
  • [41] A DIET-INDUCED MOUSE MODEL OF NONALCOHOLIC FATTY LIVER DISEASE WITH PROGRESSION TO ADVANCED FIBROSIS AND HEPATOCELLULAR CARCINOMA WITH A GENE EXPRESSION SIGNATURE MIMICKING HUMAN DISEASE
    Asgharpour, A.
    Bedossa, P.
    Hoshida, Y.
    Cazanave, S.
    Vincent, R.
    Pacana, T.
    Mirshahi, F.
    Sheneshaw, M.
    Daita, K.
    Puri, P.
    Sanyal, A.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S710 - S710
  • [42] Frizzled-4 expression enhances hepatocellular carcinoma progression, sorafenib resistance and suppresses anti-tumor CD8 T cell immunity
    Luo, Jie
    Gong, Lanqi
    Yang, Yuma
    Liu, Qin
    Huang, Jiao
    Fang, Xiaona
    Guan, Xin-Yuan
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Expression of I2-arrestin 1 in the course of mice non-alcoholic fatty liver disease progressing to hepatocellular carcinoma
    Guo, Y. W.
    Miao, H. B.
    Lin, X. Y.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 337 - 337
  • [44] Immunohistochemical evaluation of expression and distribution pattern of novel vascular markers (CD105 and D2-40) in cirrhosis and hepatocellular carcinoma
    Malhotra, R. K.
    Li, W.
    Cagle, P. T.
    Tan, D.
    MODERN PATHOLOGY, 2007, 20 : 352A - 352A
  • [45] Immunohistochemical evaluation of expression and distribution pattern of novel vascular markers (CD105 and D2-40) in cirrhosis and hepatocellular carcinoma
    Malhotra, R. K.
    Li, W.
    Cagle, P. T.
    Tan, D.
    LABORATORY INVESTIGATION, 2007, 87 : 352A - 352A
  • [46] CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients (Publication with Expression of Concern. See vol. 21, pg. 665, 2020)
    Zhang, Qing
    Chen, Xinguo
    Zhou, Jun
    Zhang, Li
    Zhao, Qingchuan
    Chen, Guangsheng
    Xu, Jing
    Qian, Feng
    Chen, Zhinan
    CANCER BIOLOGY & THERAPY, 2006, 5 (07) : 808 - 814
  • [47] Differential expression of CD44 and CD24 markers discriminates the epitheliod from the fibroblastoid subset in a sarcomatoid renal carcinoma cell line: evidence suggesting the existence of cancer stem cells in both subsets as studied with sorted cells
    Hsieh, Chin-Hsuan
    Hsiung, Shih-Chieh
    Yeh, Chi-Tai
    Yen, Chih-Feng
    Chou, Yah-Huei Wu
    Lei, Wei-Yi
    Pang, See-Tong
    Chuang, Cheng-Keng
    Liao, Shuen-Kuei
    ONCOTARGET, 2017, 8 (09) : 15593 - 15609
  • [48] Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24
    Fukushima, Tsuyoshi
    Tezuka, Tomoaki
    Shimomura, Takeshi
    Nakano, Shinichi
    Kataoka, Hiroaki
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (25) : 18634 - 18644
  • [49] Hepatic growth hormone-JAK2-STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression
    Kaltenecker, Doris
    Themanns, Madeleine
    Mueller, Kristina M.
    Spirk, Katrin
    Suske, Tobias
    Merkel, Olaf
    Kenner, Lukas
    Luis, Andreia
    Kozlov, Andrey
    Haybaeck, Johannes
    Mueller, Mathias
    Han, Xiaonan
    Moriggl, Richard
    CYTOKINE, 2019, 124
  • [50] Network-based meta-analysis of gene expression reveals novel prognostic biomarkers for the progression of hepatocellular carcinoma from non-alcoholic fatty liver disease
    Ghosh, Subhajit
    Datta, Ritobhas
    Thakur, Subarna
    HUMAN GENE, 2024, 42
12345